Login / Signup

Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU.

Yoshitaka HonmaNobuya MondenKeisuke YamazakiSatoshi KanoHironaga SatakeShigenori KadowakiYoshitaka UtsumiTomohiko NakatogawaRyo TakanoKoji FujiiYosuke KorokiJunya AoyamaShohei OuchiTetsuro OgawaSharon McCarthySabine D Brookman-MaySuneel D MundleJinhui LiDaksh ThaperToshitaka NagaoYuichiro Tada
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Although this study did not meet the predefined efficacy criteria, apalutamide plus goserelin showed clinically meaningful efficacy in a subset of patients with AR-positive SGC and safety consistent with prior experience in prostate cancer.
Keyphrases
  • prostate cancer
  • clinical trial
  • radical prostatectomy
  • randomized controlled trial
  • study protocol
  • open label